SynthesisTranslational neurodegeneration2021
Ultrasensitive assays for detection of plasma tau and phosphorylated tau 181 in Alzheimer's disease: a systematic review and meta-analysis.
Synthesis in Translational neurodegeneration, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 4 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Diagnostic value of blood p-tau subtypes in Alzheimer's disease progression and pathology: systematic review and meta-analysis.European archives of psychiatry and clinical neuroscience · 2026Pooled it
- Association between blood-based protein biomarkers and brain MRI in the Alzheimer's disease continuum: a systematic review.Journal of neurology · 2024Pooled it
- The relationship between obstructive sleep apnea and circulating tau levels: A meta-analysis.Brain and behavior · 2023Pooled it
- Lipids as Early and Minimally Invasive Biomarkers for Alzheimer's Disease.Current neuropharmacology · 2022Pooled it
- Blood-based biomarkers and early diagnosis of Alzheimer's disease.Neural regeneration research · 2026Article
- Plasma pTau181 is associated with subjective cognitive concerns but not objective cognitive decline or structural brain integrity measures in midlife.GeroScience · 2026Article
- Double cutoff strategies for plasma pTau217 to predict Tau PET positivity across multiple assay platforms: Tau-enriched and Tau-scarce cohorts for cost-effective clinical use.Alzheimer's research & therapy · 2026Article
- Cardiovascular Risk as a Moderator of the Relationship Between Plasma Alzheimer Disease Biomarkers and Cognitive Status.Journal of the American Heart Association · 2026Article
- Type 1 diabetes is associated with higher plasma levels of biomarkers of neurodegeneration and neuroinflammation.Frontiers in immunology · 2026Article
- Plasma p-Tau217 and GFAP predict widespread cognitive decline in Alzheimer's disease.Journal of neurology · 2025Article
- Short- and long-term natural history of three neurodegenerative biomarkers among middle-aged and older adults.Journal of neuromuscular diseases · 2025Article
- Associations of Plasma p-tau181 With Age, Adjusted for Kidney Function and Sociodemographic Factors.International journal of geriatric psychiatry · 2025Article
- The Cognivue Amyloid Risk Measure (CARM): A Novel Method to Predict the Presence of Amyloid with Cognivue Clarity.Neurology and therapy · 2025Article
- How well do plasma Alzheimer's disease biomarkers reflect the CSF amyloid status?Journal of neurology, neurosurgery, and psychiatry · 2025Article
- Promising clinical tools for specific Alzheimer disease diagnosis from plasma pTau217 and ApoE genotype in a cognitive disorder unit.Scientific reports · 2025Article
- CognivueJournal of Alzheimer's disease : JAD · 2025Article
- Electrochemical Technology for the Detection of Tau Proteins as a Biomarker of Alzheimer's Disease in Blood.Biosensors · 2025Review
- Association between herpes simplex virus infection and Alzheimer's disease biomarkers: analysis within the MAPT trial.Scientific reports · 2025Article
- Ferroptosis in ischemic stroke: Animal models and mechanisms.Zoological research · 2024Review
- Blood-Based Biomarkers in Frontotemporal Dementia: A Narrative Review.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
A lack of convenient and reliable biomarkers for diagnosis and prognosis is a common challenge for neurodegenerative diseases such as Alzheimer's disease (AD). Recent advancement in ultrasensitive protein assays has allowed the quantification of tau and phosphorylated tau proteins in peripheral plasma. Here we identified 66 eligible studies reporting quantification of plasma tau and phosphorylated tau 181 (ptau181) using four ultrasensitive methods. Meta-analysis of these studies confirmed that the AD patients had significantly higher plasma tau and ptau181 levels compared with controls, and that the plasma tau and ptau181 could predict AD with high-accuracy area under curve of the Receiver Operating Characteristic. Therefore, plasma tau and plasma ptau181 can be considered as biomarkers for AD diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.